Three-year real-world effectiveness, treatment persistence, and planned discontinuation of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a single-center cohort from Japan.

Emgality (galcanezumab-gnlm) - Eli Lilly, Daiichi Sankyo

Ajovy (fremanezumab-vfrm) - Teva

http://www.ncbi.nlm.nih.gov/pubmed/42211313

Akinori Futamura; Ayako Osanai; Hidetomo Murakami; Hideyo Kasai; Keita Mizuma; Kenjiro Ono; Shota Kosuge; Takeshi Kuroda; Taro Yasumoto

May 30, 2026